Ribba Benjamin
Roche Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Front Pharmacol. 2023 Feb 17;13:1094281. doi: 10.3389/fphar.2022.1094281. eCollection 2022.
Model-based approaches are instrumental for successful drug development and use. Anchored within pharmacological principles, through mathematical modeling they contribute to the quantification of drug response variability and enables precision dosing. Reinforcement learning (RL)-a set of computational methods addressing optimization problems as a continuous learning process-shows relevance for precision dosing with high flexibility for dosing rule adaptation and for coping with high dimensional efficacy and/or safety markers, constituting a relevant approach to take advantage of data from digital health technologies. RL can also support contributions to the successful development of digital health applications, recognized as key players of the future healthcare systems, in particular for reducing the burden of non-communicable diseases to society. RL is also pivotal in computational psychiatry-a way to characterize mental dysfunctions in terms of aberrant brain computations-and represents an innovative modeling approach forpsychiatric indications such as depression or substance abuse disorders for which digital therapeutics are foreseen as promising modalities.
基于模型的方法对药物的成功研发和使用至关重要。这些方法基于药理学原理,通过数学建模有助于量化药物反应变异性并实现精准给药。强化学习(RL)——作为一种将优化问题视为连续学习过程的计算方法集——对于精准给药具有相关性,它在给药规则调整方面具有高度灵活性,并且能够应对高维疗效和/或安全性指标,构成了一种利用数字健康技术数据的相关方法。强化学习还可以为数字健康应用的成功开发做出贡献,数字健康应用被视为未来医疗系统的关键参与者,特别是在减轻非传染性疾病对社会的负担方面。强化学习在计算精神病学中也至关重要——一种根据异常脑计算来表征精神功能障碍的方法——并且代表了一种针对抑郁症或药物滥用障碍等精神疾病适应症的创新建模方法,对于这些疾病,数字疗法被视为有前景的治疗方式。